Mar 15, 2023 4:01 pm EDT Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 04, 2023 4:30 pm EST Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Mar 01, 2023 4:05 pm EST Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
Feb 20, 2023 8:00 am EST Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023
Feb 14, 2023 4:01 pm EST Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nov 16, 2022 8:30 am EST Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
Jun 08, 2022 8:00 am EDT Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
Mar 15, 2022 8:00 am EDT Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer and Chief Business Officer